WallStSmart
CLYM

Climb Bio Inc

NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY

$10.12
+5.75% today

Updated 2026-10-28

Market cap
$620.31M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.91
Dividend yield
—
52W range
$2 – $18
Volume
1.5M

Climb Bio Inc (CLYM) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue—$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)———————
Cost of revenue——————$97000.00
Gross profit——————$-97000.00
Gross margin———————
R&D$4.02M$9.34M$23.32M$26.21M$15.41M$14.34M$46.62M
SG&A$677000.00$2.42M$12.35M$18.92M$24.86M$16.02M$21.17M
Operating income$-7.45M$-20.93M$-35.67M$-45.13M$-40.27M$-82.02M$-67.88M
Operating margin———————
EBITDA$-4.70M$-11.77M$-47.48M$-45.24M$-35.12M$-30.36M$-59.75M
EBITDA margin———————
EBIT$-7.45M$-20.93M$-35.67M$-45.13M$-40.27M$-82.02M$-59.85M
Interest expense———————
Income tax———————
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-6.55M$-20.67M$-47.48M$-45.24M$-35.12M$-73.90M$-59.85M
Net income growth (YoY)—-215.7%-129.7%+4.7%+22.4%-110.4%+19.0%
Profit margin———————

Frequently asked questions

How much free cash flow does CLYM generate?

CLYM produced $-54.54M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CLYM's balance sheet healthy?

CLYM holds $35.69M in cash and equivalents against — in long-term debt, on $160.47M of shareholder equity. That debt is best read against the cash flow the business throws off each year.